CL2023003564A1 - Inhibidores de la tirosina quinasa de bruton y métodos para su uso - Google Patents

Inhibidores de la tirosina quinasa de bruton y métodos para su uso

Info

Publication number
CL2023003564A1
CL2023003564A1 CL2023003564A CL2023003564A CL2023003564A1 CL 2023003564 A1 CL2023003564 A1 CL 2023003564A1 CL 2023003564 A CL2023003564 A CL 2023003564A CL 2023003564 A CL2023003564 A CL 2023003564A CL 2023003564 A1 CL2023003564 A1 CL 2023003564A1
Authority
CL
Chile
Prior art keywords
methods
tyrosine kinase
kinase inhibitors
bruton tyrosine
bruton
Prior art date
Application number
CL2023003564A
Other languages
English (en)
Spanish (es)
Inventor
Balasubramanian Sriram
Cornelissen Ivo
Guo Yue
H Leu Jocelyn
E Packman Kathryn
Alexander Palmer James
Philippar Ulrike
Rao Navin
S Tichenor Mark
D Venable Jennifer
J M Wiener John
Miao Xin
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of CL2023003564A1 publication Critical patent/CL2023003564A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CL2023003564A 2021-06-04 2023-11-29 Inhibidores de la tirosina quinasa de bruton y métodos para su uso CL2023003564A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202163196843P 2021-06-04 2021-06-04

Publications (1)

Publication Number Publication Date
CL2023003564A1 true CL2023003564A1 (es) 2024-06-21

Family

ID=82214195

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2023003564A CL2023003564A1 (es) 2021-06-04 2023-11-29 Inhibidores de la tirosina quinasa de bruton y métodos para su uso
CL2024002895A CL2024002895A1 (es) 2021-06-04 2024-09-26 Inhibidores de la tirosina quinasa de bruton y métodos de su uso.

Family Applications After (1)

Application Number Title Priority Date Filing Date
CL2024002895A CL2024002895A1 (es) 2021-06-04 2024-09-26 Inhibidores de la tirosina quinasa de bruton y métodos de su uso.

Country Status (14)

Country Link
US (1) US12622910B2 (enExample)
EP (1) EP4346834A1 (enExample)
JP (1) JP2024520630A (enExample)
KR (1) KR20240019214A (enExample)
CN (1) CN117412753A (enExample)
AU (1) AU2022284369A1 (enExample)
BR (1) BR112023025459A2 (enExample)
CA (1) CA3220015A1 (enExample)
CL (2) CL2023003564A1 (enExample)
IL (1) IL308951A (enExample)
JO (1) JOP20230310A1 (enExample)
MX (1) MX2023014435A (enExample)
TW (1) TW202317127A (enExample)
WO (1) WO2022254371A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11964976B1 (en) 2023-09-12 2024-04-23 King Faisal University Substituted pyrido[3′,4′:4,5]pyrrolo[3,2-c][1,6]naphthyridines as CK2 inhibitors
US20250333398A1 (en) 2024-04-30 2025-10-30 Boehringer Ingelheim International Gmbh Monoaryl and hetaryl substituted indazoles and benzimidazoles as sting antagonists and the use thereof as medicament
WO2025228889A1 (en) 2024-04-30 2025-11-06 Boehringer Ingelheim International Gmbh Monoarylic heterocyclic compounds as sting antagonists and the use thereof as medicament
WO2025228895A1 (en) 2024-04-30 2025-11-06 Boehringer Ingelheim International Gmbh Hetaryl substituted indazoles and benzimidazoles as sting antagonists and the use thereof as medicament
WO2025228900A1 (en) 2024-04-30 2025-11-06 Boehringer Ingelheim International Gmbh Arylamide substituted indazoles and the use thereof as medicament
WO2025228899A1 (en) 2024-04-30 2025-11-06 Boehringer Ingelheim International Gmbh Further heterocyclic compounds as sting antagonists and the use thereof as medicament
WO2025228902A1 (en) 2024-04-30 2025-11-06 Boehringer Ingelheim International Gmbh Heterocyclic acids as sting antagonists and the use thereof as medicament

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3112415A1 (de) 1981-03-28 1982-10-07 Dynamit Nobel Ag, 5210 Troisdorf Verfahren zur chlorierung von cyclischen amiden und cyclischen vinylogen amiden
US4886646A (en) 1988-03-23 1989-12-12 The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration Hanging drop crystal growth apparatus and method
US5096676A (en) 1989-01-27 1992-03-17 Mcpherson Alexander Crystal growing apparatus
US5130105A (en) 1990-10-23 1992-07-14 The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration Protein crystal growth tray assembly
US5221410A (en) 1991-10-09 1993-06-22 Schering Corporation Crystal forming device
US5430150A (en) 1992-12-16 1995-07-04 American Cyanamid Company Retroviral protease inhibitors
US5300478A (en) 1993-01-28 1994-04-05 Zeneca Limited Substituted fused pyrazolo compounds
US5400741A (en) 1993-05-21 1995-03-28 Medical Foundation Of Buffalo, Inc. Device for growing crystals
WO2003016338A1 (en) 2001-08-15 2003-02-27 Parker Hughes Institute Crystal structure of the btk kinase domain
AU2005284796A1 (en) 2004-09-15 2006-03-23 Janssen Pharmaceutica, N.V. Thiazolopyridine kinase inhibitors
US7579356B2 (en) 2005-05-04 2009-08-25 Janssen Pharmaceutica Nv Thia-tetraazaacenaphthylene kinase inhibitors
US7593820B2 (en) 2005-05-12 2009-09-22 Cytopia Research Pty Ltd Crystal structure of human Janus Kinase 2 (JAK2) and uses thereof
US7605154B2 (en) 2005-08-08 2009-10-20 Janssen Pharmaceutica N.V. Substituted Thiazolo [4,5-d]pyrimidines as protein kinase inhibitors
US7427625B2 (en) 2006-02-08 2008-09-23 Janssen Pharmaceutica, N.V. Substituted thiatriazaacenaphthylene-6-carbonitrile kinase inhibitors
EP2529621B1 (en) 2006-09-22 2016-10-05 Pharmacyclics LLC Inhibitors of bruton's tyrosine kinase
WO2010056875A1 (en) 2008-11-12 2010-05-20 Cgi Pharmaceuticals, Inc. Pyridazinones and their use as btk inhibitors
EP2471789B9 (en) 2009-08-26 2015-03-25 Takeda Pharmaceutical Company Limited Fused heterocyclic ring derivative and use thereof
WO2011133609A2 (en) 2010-04-19 2011-10-27 The Translational Genomics Research Institute Methods and kits to predict therapeutic outcome of btk inhibitors
FR2978441A1 (fr) 2011-07-25 2013-02-01 Diverchim Nouveaux analogues de ceramides, leurs procedes de preparation et leurs applications dans les compositions pharmaceutiques et cosmetiques
JP2015536446A (ja) 2012-10-11 2015-12-21 ファーマサイクリックス，インク． Ｔｅｃファミリーキナーゼ阻害剤療法のためのコンパニオン診断
EP2970291B1 (en) 2013-03-15 2022-05-11 Janssen Pharmaceutica, N.V. Processes and intermediates for preparing a medicament
HRP20181109T1 (hr) 2013-12-11 2018-11-02 Biogen Ma Inc. Spojevi biarila korisni za liječenje ljudskih bolesti u onkologiji, neurologiji i imunologiji
WO2015127261A1 (en) 2014-02-21 2015-08-27 Pharmacyclics, Inc. Biomarkers for predicting response of dlbcl to treatment with ibrutinib
BR112017001677A2 (pt) 2014-08-01 2018-07-17 Pharmacyclics Llc biomarcadores para predizer resposta de dlbcl ao tratamento com um inibidor de btk
SMT202100674T1 (it) * 2014-08-11 2022-01-10 Acerta Pharma Bv Combinazioni terapeutiche di un inibitore di btk e un inibitore di bcl-2
JO3794B1 (ar) * 2015-12-10 2021-01-31 Janssen Pharmaceutica Nv المركبات متعددة الحلقات كمثبطات لتيروزين كيناز بروتون
JO3793B1 (ar) 2015-12-10 2021-01-31 Janssen Pharmaceutica Nv مثبطات تيروزين كاينيز بروتون وأساليب استخدامها
WO2018103058A1 (en) 2016-12-09 2018-06-14 Janssen Pharmaceutica Nv Inhibitors of bruton's tyrosine kinase and methods of their use
WO2018103060A1 (en) * 2016-12-09 2018-06-14 Janssen Pharmaceutica Nv Inhibitors of bruton's tyrosine kinase and methods of their use
JP2023522957A (ja) 2020-04-21 2023-06-01 フラッグシップ パイオニアリング， インコーポレイテッド 二機能性分子およびその使用方法
MX2024010134A (es) 2022-02-18 2024-08-27 Janssen Pharmaceutica Nv Sintesis de inhibidores de tirosina quinasa de bruton.

Also Published As

Publication number Publication date
WO2022254371A1 (en) 2022-12-08
US12622910B2 (en) 2026-05-12
EP4346834A1 (en) 2024-04-10
TW202317127A (zh) 2023-05-01
BR112023025459A2 (pt) 2024-02-27
IL308951A (en) 2024-01-01
US20230013755A1 (en) 2023-01-19
CN117412753A (zh) 2024-01-16
JP2024520630A (ja) 2024-05-24
JOP20230310A1 (ar) 2023-11-29
MX2023014435A (es) 2024-03-08
AU2022284369A1 (en) 2024-01-25
CA3220015A1 (en) 2022-12-08
KR20240019214A (ko) 2024-02-14
CL2024002895A1 (es) 2025-02-14

Similar Documents

Publication Publication Date Title
MX2023014435A (es) Inhibidores de la tirosina quinasa de bruton y métodos de su uso.
CL2022002985A1 (es) Inhibidores de pi3k y métodos de uso de los mismos
MX386700B (es) Inhibidores de la tirosina quinasa de bruton y metodos de su uso.
EA201070480A1 (ru) Ингибиторы с-fms киназы
MX2022013941A (es) Inhibidores de imino sulfanona de enpp1.
ATE499097T1 (de) Monozyklische heterozyklen als kinase-hemmer
UY37015A (es) Inhibidores de la tirosina quinasa de bruton y métodos de su uso
AR113901A1 (es) Uso tópico y entrega de microorganismos oxidantes de amoniaco
PH12019500770A1 (en) Process for the synthesis of an indoleamine 2,3-dioxygenase inhibitor
EA201992137A1 (ru) ПИРИМИДОПИРИМИДИНОНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ КИНАЗЫ Wee-1
MX2022002946A (es) Inhibidores de cdk y su uso como productos farmaceuticos.
ECSP23057264A (es) Inhibidores de cdk2 y métodos de uso de los mismos
EA201000094A1 (ru) Производные пиримидинил-пиридазинона
MX2023007265A (es) Inhibidores de cdk y su uso como productos farmacéuticos.
EA201201170A1 (ru) Гетариламинонафтиридины
UY38233A (es) Agentes inhibidores para la tirosina cinasa de bruton
UY28441A1 (es) Derivados de quinazolina
DE10334663A1 (de) Harnstoffderivate
CL2023001637A1 (es) Inhibidores de la vía jak1 para el tratamiento del vitíligo.
PE20151494A1 (es) Proceso novedoso para la elaboracion de compuestos para su uso en el tratamiento del cancer
IL286983A (en) Methods of treating chronic spontaneous urticaria using a bruton's tyrosine kinase inhibitor
DOP2013000207A (es) Derivados de piridinilo y pirazinil-metiloxi-arilo utiles como inhibidores de la tirosina cinasa del bazo (syk)
MX2023015121A (es) Metodos de uso de inhibidores de aldosterona sintasa.
EA201800445A1 (ru) Соединение в виде амино-замещенно шестичленного гетероциклического кольца с гетероатомом азота, его получение и использование
MX2024010134A (es) Sintesis de inhibidores de tirosina quinasa de bruton.